[wpseo_breadcrumb]

HR Insights Blog Header All adults in the United States are now eligible for COVID-19 vaccines. With vaccine distribution reaching the general public, a growing proportion of the workforce is now vaccinated.

In turn, many of these vaccinated employees have also received a vaccine card. It’s worthwhile for employers to understand what COVID-19 vaccine cards are and what uses they may have in the workplace. This article provides an overview of COVID-19 vaccine cards and considerations for supporting employees that have COVID-19 vaccine cards.

[wpseo_breadcrumb]

HR Compliance Bulletin header image The U.S. Department of Labor’s (DOL) Wage and Hour Division (WHD) has updated its “COVID-19 and the Family and Medical Leave Act Questions and Answers” web page, originally published in 2020.

As before, the Q&As explain that—under the FMLA—covered employers must provide eligible employees with job-protected, unpaid leave for specified family and medical reasons. Additionally, employees on FMLA leave are entitled to the continuation of group health insurance coverage under the same terms that were in effect before they took leave.

[wpseo_breadcrumb]

HR Compliance Bulletin header image In response to the coronavirus (COVID-19) pandemic, states have passed new laws and issued new regulations and guidance about employee leave taken for COVID-19 reasons.

These provisions are in addition to the federal Emergency Paid Sick Leave Act and Emergency Family and Medical Leave Expansion Act, passed on March 18 as part of the Families First Coronavirus Response Act (FFCRA).

[wpseo_breadcrumb]

Legal Update Header On Apr. 20, 2021, the Occupational Safety and Health Administration (OSHA) provided guidance for recording COVID-19 vaccination adverse reactions.

The guidance comes in the format of frequently asked questions for adverse reactions under two scenarios: employer-required and voluntary vaccination.

Employer-required Vaccination

According to OSHA’s guidance, employers are required to record adverse reactions to the vaccine if the reactions are:

[wpseo_breadcrumb]

News Brief header In a joint statement, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have recommended lifting a pause on the distribution of the Johnson & Johnson (J&J) COVID-19 vaccine.

On April 13, the agencies recommended a pause on the J&J one-dose vaccine after reports of six cases of a rare and severe type of blood clot in individuals following administration of the vaccine. Reports of adverse events following the use of the J&J vaccine suggested an increased risk of a rare adverse event called thrombosis with thrombocytopenia syndrome (TTS). Nearly all reports of this serious condition, which involves blood clots with low platelets, have been in adult women under the age of 50.